Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2009 - 2026)

Regeneron Pharmaceuticals has reported Cash & Equivalents for 18 years, with the latest figure at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 4.13% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (down 4.13% YoY), and the FY2025 full-year result was $3.1 billion, up 25.32% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $3.0 billion, down from $3.1 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.9 billion in Q1 2023, with the low at $1.9 billion in Q2 2024.
• Average Cash & Equivalents over 5 years is $2.8 billion, with a median of $2.7 billion recorded in 2023.
• Year-over-year, Cash & Equivalents surged 132.68% in 2022 and tumbled 42.94% in 2023.
• Tracing REGN's Cash & Equivalents over 5 years: stood at $3.1 billion in 2022, then dropped by 12.1% to $2.7 billion in 2023, then decreased by 8.86% to $2.5 billion in 2024, then climbed by 25.32% to $3.1 billion in 2025, then declined by 4.99% to $3.0 billion in 2026.
• The last three Cash & Equivalents figures came in at $3.0 billion (Q1 2026), $3.1 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.

Peer Comparison